Diflomotecan Uses, Dosage, Side Effects and more
Diflomotecan is under investigation in clinical trial NCT00080015 (Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)).
| Trade Name | Diflomotecan |
| Generic | Diflomotecan |
| Diflomotecan Other Names | Diflomotecan |
| Type | |
| Formula | C21H16F2N2O4 |
| Weight | Average: 398.366 Monoisotopic: 398.107813329 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
